Virological response to interferon therapy of chronic hepatitis B as measured by a highly sensitive assay

Authors

  • M. Lindh,

    1. Department of Clinical Virology, Göteborg University, Göteborg, Sweden, and Clinical Research Unit, Hvidovre Hospital, Copenhagen, Denmark
    Search for more papers by this author
  • C. Hannoun,

    1. Department of Clinical Virology, Göteborg University, Göteborg, Sweden, and Clinical Research Unit, Hvidovre Hospital, Copenhagen, Denmark
    Search for more papers by this author
  • P. Horal,

    1. Department of Clinical Virology, Göteborg University, Göteborg, Sweden, and Clinical Research Unit, Hvidovre Hospital, Copenhagen, Denmark
    Search for more papers by this author
  • K. Krogsgaard,

    1. Department of Clinical Virology, Göteborg University, Göteborg, Sweden, and Clinical Research Unit, Hvidovre Hospital, Copenhagen, Denmark
    Search for more papers by this author
  • the INTERPRED Study Group

    1. Department of Clinical Virology, Göteborg University, Göteborg, Sweden, and Clinical Research Unit, Hvidovre Hospital, Copenhagen, Denmark
    Search for more papers by this author

Magnus Lindh Department of Clinical Virology, Göteborg University, Guldhedsgatan 10B, S-413 46 Göteborg, Sweden. E-mail: magnus.lindh@microbio.gu.se

Abstract

In the interferon (IFN) treatment of chronic hepatitis B, there is no accepted definition of virological response as measured by highly sensitive HBV DNA assays. In the present study of 98 patients given IFN (10 MU/day for 1 week, then 10 MU TIW for 11 weeks) with or without prednisolone priming, a virological response was identified as log HBV DNA/mL below 6.0 (by Amplicor Monitor, Roche) 6 months post-treatment. At this time, 92% (33/36) of the sustained responders (SR) still had detectable viraemia with log HBV DNA/mL at 4.30 ± 0.15 (± SEM), as compared with 8.69 ± 0.097 in nonsustained responders. Pretreatment viraemia below a threshold at 500 million copies/mL was associated with higher chance of response (P=0.023). Prednisolone enhanced the sustained response (53% vs. 30%, P=0.025), and in particular end-of-treatment response (ETR, 50% vs. 10%, P < 0.0001). ETR was predictive for SR (P < 0.0001), especially when log HBV DNA/mL was < 4.0 (PPV=92%). The potential value of differentiating the therapy of chronic hepatitis B on the basis of viraemia levels, as measured by highly sensitive assays, should be further investigated.

Ancillary